Immunotherapy of glioblastoma: Recent advances and future prospects

References

• Ostrom QT, Gittleman H, Stetson L, Virk SM, Barnholtz-Sloan JS. Epidemiology of gliomas. Cancer Treat Res. 2015;163:1–16.
   PubMedGoogle Scholar
• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96. doi:10.1056/NEJMoa043330.
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase iii study: 5-year analysis of the eortc-ncic trial. Lancet Oncol. 2009;10(5):459–66. doi:10.1016/S1470-2045(09)70025-7.
   PubMed Web of Science ®Google Scholar
• Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet. 2018;392(10145):432–46. doi:10.1016/S0140-6736(18)30990-5.
   PubMed Web of Science ®Google Scholar
• Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from t cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651–68. doi:10.1038/s41577-020-0306-5.
   PubMed Web of Science ®Google Scholar
• Jackson C, Choi J, Lim M. Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nat Immunol. 2019;20(9):1100–09. doi:10.1038/s41590-019-0433-y.
   PubMed Web of Science ®Google Scholar
• Bauer H-C, Krizbai IA, Bauer H, Traweger A. “You shall not pass”-tight junctions of the blood brain barrier. Front Neurosci. 2014;8. doi:10.3389/fnins.2014.00392.
   Web of Science ®Google Scholar
• Campos-Bedolla P, Walter FR, Veszelka S, Deli MA. Role of the blood-brain barrier in the nutrition of the central nervous system. Arch Med Res. 2014;45(8):610–38. doi:10.1016/j.arcmed.2014.11.018.
   PubMed Web of Science ®Google Scholar
• Le Guennec L, Coureuil M, Nassif X, Bourdoulous S. Strategies used by bacterial pathogens to cross the blood-brain barrier. Cell Microbiol. 2020;22(1):e13132. doi:10.1111/cmi.13132.
   PubMed Web of Science ®Google Scholar
• Ransohoff RM, Cardona AE. The myeloid cells of the central nervous system parenchyma. Nature. 2010;468(7321):253–62. doi:10.1038/nature09615.
   PubMed Web of Science ®Google Scholar
• Coureuil M, Lecuyer H, Bourdoulous S, Nassif X. A journey into the brain: insight into how bacterial pathogens cross blood-brain barriers. Nat Rev Microbiol. 2017;15(3):149–59. doi:10.1038/nrmicro.2016.178.
   PubMed Web of Science ®Google Scholar
• Lecuyer M-A, Kebir H, Prat A. Glial influences on bbb functions and molecular players in immune cell trafficking. Biochim Biophys Acta, Mol Basis Dis. 2016;1862(3):472–82. doi:10.1016/j.bbadis.2015.10.004.
   PubMed Web of Science ®Google Scholar
• Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell JW, Lee KS, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523(7560):337±. doi:10.1038/nature14432.
   PubMed Web of Science ®Google Scholar
• Marchetti L, Engelhardt B. Immune cell trafficking across the blood-brain barrier in the absence and presence of neuroinflammation. Vasc Biol. 2020;2(1):H1–H18. doi:10.1530/VB-19-0033.
   PubMedGoogle Scholar
• Tomaszewski W, Sanchez-Perez L, Gajewski TF, Sampson JH. Brain tumor microenvironment and host state: implications for immunotherapy. Clin Cancer Res. 2019;25(14):4202–10. doi:10.1158/1078-0432.CCR-18-1627.
   PubMed Web of Science ®Google Scholar
• Sottoriva A, Spiteri I, Piccirillo SGM, Touloumis A, Collins VP, Marioni JC, Curtis C, Watts C, Tavare S. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A. 2013;110(10):4009–14. doi:10.1073/pnas.1219747110.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The three es of cancer immunoediting. Annu Rev Immunol. 2004;22(1):329–60. doi:10.1146/annurev.immunol.22.012703.104803.
   PubMed Web of Science ®Google Scholar
• Memarnejadian A, Meilleur CE, Shaler CR, Khazaie K, Bennink JR, Schell TD, Haeryfar SMM. Pd-1 blockade promotes epitope spreading in anticancer cd8(+) t cell responses by preventing fratricidal death of subdominant clones to relieve immunodomination. J Immunol. 2017;199(9):3348–59. doi:10.4049/jimmunol.1700643.
   PubMed Web of Science ®Google Scholar
• Markovic DS, Glass R, Synowitz M, van Rooijen N, Kettenmann H. Microglia stimulate the invasiveness of glioma cells by increasing the activity of metalloprotease-2. J Neuropathol Exp Neurol. 2005;64(9):754–62. doi:10.1097/01.jnen.0000178445.33972.a9.
   PubMed Web of Science ®Google Scholar
• Yeung YT, Bryce NS, Adams S, Braidy N, Konayagi M, McDonald KL, Teo C, Guillemin GJ, Grewal T, Munoz L. P38 mapk inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human u251 glioblastoma cells. J Neurooncol. 2012;109(1):35–44. doi:10.1007/s11060-012-0875-7.
   PubMed Web of Science ®Google Scholar
• Rempel SA, Dudas S, Ge SG, Gutierrez JA. Identification and localization of the cytokine sdf1 and its receptor, cxc chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin Cancer Res. 2000;6:102–11.
   PubMed Web of Science ®Google Scholar
• Pan Y, Yu Y, Wang X, Zhang T. Tumor-Associated macrophages in tumor immunity. Front Immunol. 2020;11. doi:10.3389/fimmu.2020.583084.
   Web of Science ®Google Scholar
• Alban TJ, Alvarado AG, Sorensen MD, Bayik D, Volovetz J, Serbinowski E, Mulkearns-Hubert EE, Sinyuk M, Hale JS, Onzi GR, et al. Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. Jci Insight. 2018;3(21). doi:10.1172/jci.insight.122264.
   PubMed Web of Science ®Google Scholar
• Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K, Ouyang G-F, Okada M, Balazs M, Adany R, et al. Tumor-Infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear m1- and m2-type characteristics. J Leukoc Biol. 2008;83(5):1136–44. doi:10.1189/jlb.0907611.
   PubMed Web of Science ®Google Scholar
• Zhu X, Fujita M, Snyder LA, Okada H. Systemic delivery of neutralizing antibody targeting ccl2 for glioma therapy. J Neurooncol. 2011;104(1):83–92. doi:10.1007/s11060-010-0473-5.
   PubMed Web of Science ®Google Scholar
• Wu C-J, Chen C-H, Lin C-Y, Feng L-Y, Lin Y-C, Wei K-C, Huang C-Y, Fang J-Y, Chen P-Y. Ccl5 of glioma-associated microglia/macrophages regulates glioma migration and invasion via calcium-dependent matrix metalloproteinase 2. Neuro-Oncology. 2020;22(2):253–66. doi:10.1093/neuonc/noz189.
   PubMed Web of Science ®Google Scholar
• Jordan JT, Sun W, Hussain SF, DeAngulo G, Prabhu SS, Heimberger AB. Preferential migration of regulatory t cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother. 2008;57(1):123–31. doi:10.1007/s00262-007-0336-x.
   PubMed Web of Science ®Google Scholar
• Humphries W, Wei J, Sampson JH, Heimberger AB. The role of tregs in glioma-mediated immunosuppression: potential target for intervention. Neurosurg Clin N Am. 2010;21(1):125±. doi:10.1016/j.nec.2009.08.012.
   PubMed Web of Science ®Google Scholar
• De I, Steffen MD, Clark PA, Patros CJ, Sokn E, Bishop SM, Litscher S, Maklakova VI, Kuo JS, Rodriguez FJ, Maklakova VI, et al. Csf1 overexpression promotes high-grade glioma formation without impacting the polarization status of glioma-associated microglia and macrophages. Cancer Res. 2016;76(9):2552–60. doi:10.1158/0008-5472.CAN-15-2386.
   PubMed Web of Science ®Google Scholar
• Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, et al. Orally administered colony stimulating factor 1 receptor inhibitor plx3397 in recurrent glioblastoma: an ivy foundation early phase clinical trials consortium phase ii study. Neuro-Oncology. 2016;18(4):557–64. doi:10.1093/neuonc/nov245.
   PubMed Web of Science ®Google Scholar
• Quail DF, Bowman RL, Akkari L, Quick ML, Schuhmacher AJ, Huse JT, Holland EC, Sutton JC, Joyce JA. The tumor microenvironment underlies acquired resistance to csf-1r inhibition in gliomas. Science. 2016;352(6288):352(6288. doi:10.1126/science.aad3018.
   PubMed Web of Science ®Google Scholar
• Takenaka MC, Gabriely G, Rothhammer V, Mascanfroni ID, Wheeler MA, Chao C-C, Gutierrez-Vazquez C, Kenison J, Tjon EC, Barroso A, et al. Control of tumor-associated macrophages and t cells in glioblastoma via ahr and cd39. Nat Neurosci. 2019;22(5):729±. doi:10.1038/s41593-019-0370-y.
   Web of Science ®Google Scholar
• Junnikkala S, Jokiranta TS, Friese MA, Jarva H, Zipfel PF, Meri S. Exceptional resistance of human h2 glioblastoma cells to complement-mediated killing by expression and utilization of factor h and factor h-like protein 1. J Immunol. 2000;164(11):6075–81. doi:10.4049/jimmunol.164.11.6075.
   PubMed Web of Science ®Google Scholar
• Foernvik K, Maddahi A, Persson O, Osther K, Salford LG, Redebrandt HN. C1-Inactivator is upregulated in glioblastoma. Plos One. 2017;12(9): e0183086.
   PubMed Web of Science ®Google Scholar
• Lim M, Xia Y, Bettegowda C, Weller M. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018;15(7):422–42. doi:10.1038/s41571-018-0003-5.
   PubMed Web of Science ®Google Scholar
• Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of car t cells. Nat Rev Cancer. 2021;21(3):145–61. doi:10.1038/s41568-020-00323-z.
   PubMed Web of Science ®Google Scholar
• Benmebarek M-R, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing mechanisms of chimeric antigen receptor (car) t cells. Int J Mol Sci. 2019;20(6):1283. doi:10.3390/ijms20061283.
   PubMed Web of Science ®Google Scholar
• Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, Bleakley M, Brown C, Mgebroff S, Kelly-Spratt KS, et al. Intent-To-Treat leukemia remission by cd19 car t cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322–31. doi:10.1182/blood-2017-02-769208.
   PubMed Web of Science ®Google Scholar
• Mintz A, Gibo DM, Slagle-Webb B, Christensen ND, Debinski W. Il-13r alpha 2 is a glioma-restricted receptor for interleukin-13. Neoplasia. 2002;4(5):388–99. doi:10.1038/sj.neo.7900234.
   PubMed Web of Science ®Google Scholar
• Thaci B, Brown CE, Binello E, Werbaneth K, Sampath P, Sengupta S. Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. Neuro-Oncology. 2014;16(10):1304–12. doi:10.1093/neuonc/nou045.
   PubMed Web of Science ®Google Scholar
• Tu M, Wange W, Cai L, Zhu P, Gao Z, Zheng W. Il-13 receptor alpha 2 stimulates human glioma cell growth and metastasis through the src/pi3k/akt/mtor signaling pathway. Tumor Biol. 2016;37(11):14701–09. doi:10.1007/s13277-016-5346-x.
   PubMedGoogle Scholar
• Brown CE, Warden CD, Starr R, Deng X, Badie B, Yuan Y-C, Forman SJ, Barish ME. Glioma IL13Rα2 is associated with mesenchymal signature gene expression and poor patient prognosis. Plos One. 2013;8(10):e77769. doi:10.1371/journal.pone.0077769.
   PubMed Web of Science ®Google Scholar
• Kong S, Sengupta S, Tyler B, Bais AJ, Ma Q, Doucette S, Zhou J, Sahin A, Carter BS, Brem H, et al. Suppression of human glioma xenografts with second-generation il13r-specific chimeric antigen receptor-modified t cells. Clin Cancer Res. 2012;18(21):5949–60. doi:10.1158/1078-0432.CCR-12-0319.
   PubMed Web of Science ®Google Scholar
• Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang W-C, Naranjo A, Starr R, Wagner J, Wright C, et al. Bioactivity and safety of il13r alpha 2-redirected chimeric antigen receptor cd8(+) t cells in patients with recurrent glioblastoma. Clin Cancer Res. 2015;21(18):4062–72. doi:10.1158/1078-0432.CCR-15-0428.
   PubMed Web of Science ®Google Scholar
• Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, et al. Regression of glioblastoma after chimeric antigen receptor t-cell therapy. N Engl J Med. 2016;375(26):2561–69. doi:10.1056/NEJMoa1610497.
   PubMed Web of Science ®Google Scholar
• Padfield E, Ellis HP, Kurian KM. Current therapeutic advances targeting egfr and egfrviii in glioblastoma. Front Oncol. 2015;5. doi:10.3389/fonc.2015.00005.
   PubMed Web of Science ®Google Scholar
• Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor receptor variant iii (egfrviii): where wild things are altered. Febs J. 2013;280(21):5350–70. doi:10.1111/febs.12393.
   PubMed Web of Science ®Google Scholar
• Felsberg J, Hentschel B, Kaulich K, Gramatzki D, Zacher A, Malzkorn B, Kamp M, Sabel M, Simon M, Westphal M, et al. Epidermal growth factor receptor variant iii (egfrviii) positivity in egfr-amplified glioblastomas: prognostic role and comparison between primary and recurrent tumors. Clin Cancer Res. 2017;23(22):6846–55. doi:10.1158/1078-0432.CCR-17-0890.
   PubMed Web of Science ®Google Scholar
• Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace AK, Dentchev T, Thekkat P, Loew A, et al. Rational development and characterization of humanized anti-egfr variant iii chimeric antigen receptor t cells for glioblastoma. Sci Transl Med. 2015;7(275). doi:10.1126/scitranslmed.aaa4963.
   Google Scholar
• O’-Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, et al. A single dose of peripherally infused egfrviii-directed car t cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399). doi:10.1126/scitranslmed.aaa0984.
   PubMed Web of Science ®Google Scholar
• Goff SL, Morgan RA, Yang JC, Sherry RM, Robbins PF, Restifo NP, Feldman SA, Lu Y-C, Lu L, Zheng Z, et al. Pilot trial of adoptive transfer of chimeric antigen receptor–transduced T cells targeting EGFRvIII in patients with glioblastoma. J Immunother. 2019;42(4):126–35. doi:10.1097/CJI.0000000000000260.
   PubMed Web of Science ®Google Scholar
• Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, Bailey SR, Boroughs AC, Frigault MJ, Leick MB, et al. Car-T cells secreting bites circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019;37(9):1049±. doi:10.1038/s41587-019-0192-1.
   PubMed Web of Science ®Google Scholar
• Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, Downey KM, Yu W, Carrera DA, Celli A, et al. Synnotch-Car t cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021;13(591). doi:10.1126/scitranslmed.abe7378.
   Web of Science ®Google Scholar
• Picarda E, Ohaegbulam KC, Zang X. Molecular pathways: targeting b7-h3 (cd276) for human cancer immunotherapy. Clin Cancer Res. 2016;22(14):3425–31. doi:10.1158/1078-0432.CCR-15-2428.
   PubMed Web of Science ®Google Scholar
• Yang S, Wei W, Zhao Q. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy. Int J Biol Sci. 2020;16(11):1767–73. doi:10.7150/ijbs.41105.
   PubMed Web of Science ®Google Scholar
• Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota C, et al. Car t cells targeting b7-h3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res. 2019;25(8):2560–74. doi:10.1158/1078-0432.CCR-18-0432.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Luther N, Ibrahim GM, Hawkins C, Vibhakar R, Handler MH, Souweidane MM. B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma. J Neurooncol. 2013;111(3):257–64. doi:10.1007/s11060-012-1021-2.
   PubMed Web of Science ®Google Scholar
• Tang X, Zhao S, Zhang Y, Wang Y, Zhang Z, Yang M, Zhu Y, Zhang G, Guo G, Tong A, et al. B7-H3 as a novel car-t therapeutic target for glioblastoma. Mol Ther-Oncolytics. 2019;14:279–87. doi:10.1016/j.omto.2019.07.002.
   PubMed Web of Science ®Google Scholar
• Tang X, Wang Y, Huang J, Zhang Z, Liu F, Xu J, Guo G, Wang W, Tong A, Zhou L. Administration of b7-h3 targeted chimeric antigen receptor-t cells induce regression of glioblastoma. Signal Transduction Targeted Ther. 2021;6(1). doi:10.1038/s41392-021-00505-7.
   Web of Science ®Google Scholar
• Huang J, Zheng M, Zhang Z, Tang X, Chen Y, Peng A, Peng X, Tong A, Zhou L. Interleukin-7-Loaded oncolytic adenovirus improves car-t cell therapy for glioblastoma. Cancer Immunol Immunother. 2021;70(9):2453–65. doi:10.1007/s00262-021-02856-0.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Salsman VS, Kew Y, Shaffer D, Powell S, Zhang YJ, Grossman RG, Heslop HE, Gottschalk S. Her2-Specific t cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res. 2010;16(2):474–85. doi:10.1158/1078-0432.CCR-09-1322.
   PubMed Web of Science ®Google Scholar
• Zhang JG, Kruse CA, Driggers L, Hoa N, Wisoff J, Allen JC, Zagzag D, Newcomb EW, Jadus MR. Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy. J Neurooncol. 2008;88(1):65–76. doi:10.1007/s11060-008-9534-4.
   PubMed Web of Science ®Google Scholar
• Pienkowski T, Zielinski CC. Trastuzumab treatment in patients with breast cancer and metastatic cns disease. Ann Oncol. 2010;21(5):917–24. doi:10.1093/annonc/mdp353.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, et al. Her2-Specific chimeric antigen receptor-modified virus-specific t cells for progressive glioblastoma a phase 1 dose-escalation trial. Jama Oncol. 2017;3(8):1094–101. doi:10.1001/jamaoncol.2017.0184.
   PubMed Web of Science ®Google Scholar
• Vitanza NA, Johnson AJ, Wilson AL, Brown C, Yokoyama JK, Kunkele A, Chang CA, Rawlings-Rhea S, Huang W, Seidel K, et al. Locoregional infusion of her2-specific car t cells in children and young adults with recurrent or refractory cns tumors: an interim analysis. Nat Med. 2021;27(9):1544±. doi:10.1038/s41591-021-01404-8.
   PubMed Web of Science ®Google Scholar
• Bielamowicz K, Fousek K, Byrd TT, Samaha H, Mukherjee M, Aware N, Wu M-F, Orange JS, Sumazin P, Man T-K, et al. Trivalent car t cells overcome interpatient antigenic variability in glioblastoma. Neuro-Oncology. 2018;20(4):506–18. doi:10.1093/neuonc/nox182.
   PubMed Web of Science ®Google Scholar
• Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014;14(8):559–67. doi:10.1038/nrc3770.
   PubMed Web of Science ®Google Scholar
• Russell SJ, Barber GN. Oncolytic viruses as antigen-agnostic cancer vaccines. Cancer Cell. 2018;33(4):599–605. doi:10.1016/j.ccell.2018.03.011.
   PubMed Web of Science ®Google Scholar
• Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y, Guo ZS. Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer. 2013;12(1):1–16. doi:10.1186/1476-4598-12-103.
   PubMedGoogle Scholar
• Chiocca EA, Rabkin SD. Chiocca EA and Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res. 2014;2(4):295–300. doi:10.1158/2326-6066.CIR-14-0015.
   PubMed Web of Science ®Google Scholar
• Brown MC, Holl EK, Boczkowski D, Dobrikova E, Mosaheb M, Chandramohan V, Bigner DD, Gromeier M, Nair SK. Cancer immunotherapy with recombinant poliovirus induces ifn-dominant activation of dendritic cells and tumor antigen-specific ctls. Sci Transl Med. 2017;9(408). doi:10.1126/scitranslmed.aan4220.
   Web of Science ®Google Scholar
• Hardcastle J, Mills L, Malo CS, Jin F, Kurokawa C, Geekiyanage H, Schroeder M, Sarkaria J, Johnson AJ, Galanis E. Immunovirotherapy with measles virus strains in combination with anti-pd-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Neuro-Oncology. 2017;19(4):493–502. doi:10.1093/neuonc/now179.
   PubMed Web of Science ®Google Scholar
• Rajaraman S, Canjuga D, Ghosh M, Codrea MC, Sieger R, Wedekink F, Tatagiba M, Koch M, Lauer UM, Nahnsen S, et al. Measles virus-based treatments trigger a pro-inflammatory cascade and a distinctive immunopeptidome in glioblastoma. Mol Ther-Oncolytics. 2019;12:147–61. doi:10.1016/j.omto.2018.12.010.
   PubMed Web of Science ®Google Scholar
• Kiyokawa J, Wakimoto H. Preclinical and clinical development of oncolytic adenovirus for the treatment of malignant glioma. Oncolytic Virother. 2019;8:27–37. doi:10.2147/OV.S196403.
   PubMed Web of Science ®Google Scholar
• Alessandrini F, Menotti L, Avitabile E, Appolloni I, Ceresa D, Marubbi D, Campadelli-Fiume G, Malatesta P. Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic hsv in a preclinical model. Oncogene. 2019;38(23):4467–79. doi:10.1038/s41388-019-0737-2.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Mesci P, Bernatchez JA, Gimple RC, Wang X, Schafer ST, Wettersten HI, Beck S, Clark AE, Wu Q, et al. Zika virus targets glioblastoma stem cells through a sox2-integrin alpha(v)beta(5) axis. Cell Stem Cell. 2020;26(2):187±. doi:10.1016/j.stem.2019.11.016.
   Web of Science ®Google Scholar
• Pol J, Buque A, Aranda F, Bloy N, Cremer I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher J-M, et al. Trial watch—Oncolytic viruses and cancer therapy. Oncoimmunology. 2016;5(2):e1117740. doi:10.1080/2162402X.2015.1117740.
   PubMed Web of Science ®Google Scholar
• Fulci G, Chiocca EA. Oncolytic viruses for the therapy of brain tumors and other solid malignancies: a review. Front Biosci-Landmark. 2003;8:E346–E360. doi:10.2741/976.
   PubMed Web of Science ®Google Scholar
• Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F, Kracher J, Grossman SA, Fisher JD, Carson K, et al. A phase i open-label, dose-escalation, multi-institutional trial of injection with an e1b-attenuated adenovirus, onyx-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther. 2004;10(5):958–66. doi:10.1016/j.ymthe.2004.07.021.
   PubMed Web of Science ®Google Scholar
• Kemeny N, Brown K, Covey A, Kim T, Bhargava A, Brody L, Guilfoyle B, Haag NP, Karrasch M, Glasschroeder B, et al. Phase i, open-label, dose-escalating study of a genetically engineered herpes simplex virus, nv1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther. 2006;17(12):1214–24. doi:10.1089/hum.2006.17.1214.
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Landolfi J, Vogelbaum MA, Ostertag D, Elder JB, Bloomfield S, Carter B, Chen CC, Kalkanis SN, Kesari S, et al. Durable complete responses in some recurrent high grade glioma patients treated with toca 511+toca fc. Neuro-Oncology. 2018;20(10):1383–92. doi:10.1093/neuonc/noy075.
   PubMed Web of Science ®Google Scholar
• Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA, Liu TJ, Jiang H, Lemoine MG, Suzuki K, et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst. 2003;95(9):652–60. doi:10.1093/jnci/95.9.652.
   PubMed Web of Science ®Google Scholar
• Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, Prabhu SS, Rao G, Fuller GN, Aldape KD, et al. Phase i study of dnx-2401 (delta-24-rgd) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018;36(14):1419±. doi:10.1200/JCO.2017.75.8219.
   Web of Science ®Google Scholar
• Geletneky K, Hajda J, Angelova AL, Leuchs B, Capper D, Bartsch AJ, Neumann J-O, Schoening T, Huesing J, Beelte B, et al. Oncolytic h-1 parvovirus shows safety and signs of immunogenic activity in a first phase i/iia glioblastoma trial. Mol Ther. 2017;25(12):2620–34. doi:10.1016/j.ymthe.2017.08.016.
   PubMed Web of Science ®Google Scholar
• Gromeier M, Alexander L, Wimmer E. Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Proc Natl Acad Sci U S A. 1996;93(6):2370–75. doi:10.1073/pnas.93.6.2370.
   PubMed Web of Science ®Google Scholar
• Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell. 1989;56(5):855–65. doi:10.1016/0092-8674(89)90690-9.
   PubMed Web of Science ®Google Scholar
• Chandramohan V, Bryant JD, Piao H, Keir ST, Lipp ES, Lefaivre M, Perkinson K, Bigner DD, Gromeier M, McLendon RE. Validation of an immunohistochemistry assay for detection of cd155, the poliovirus receptor, in malignant gliomas. Arch Pathol & Lab Med. 2017;141(12):1697–704. doi:10.5858/arpa.2016-0580-OA.
   PubMed Web of Science ®Google Scholar
• Takai Y, Miyoshi J, Ikeda W, Ogita H. Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation. Nat Rev Mol Cell Biol. 2008;9(8):603–15. doi:10.1038/nrm2457.
   PubMed Web of Science ®Google Scholar
• Desjardins A, Gromeier M, Herndon JE II, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, et al. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med. 2018;379(2):150–61. doi:10.1056/NEJMoa1716435.
   PubMed Web of Science ®Google Scholar
• Advani SJ, Markert JM, Sood RF, Samuel S, Gillespie GY, Shao MY, Roizman B, Weichselbaum RR. Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of hsv-1. Gene Ther. 2011;18(11):1098–102. doi:10.1038/gt.2011.61.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642±. doi:10.1038/nrd4663.
   PubMed Web of Science ®Google Scholar
• Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995;1(9):938–43. doi:10.1038/nm0995-938.
   PubMed Web of Science ®Google Scholar
• Friedman GK, Johnston JM, Bag AK, Bernstock JD, Li R, Aban I, Kachurak K, Nan L, Kang KD, Totsch S, et al. Oncolytic hsv-1 g207 immunovirotherapy for pediatric high-grade gliomas. N Engl J Med. 2021;384(17):1613–22. doi:10.1056/NEJMoa2024947.
   PubMed Web of Science ®Google Scholar
• Sugawara K, Iwai M, Yajima S, Tanaka M, Yanagihara K, Seto Y, Todo T. Efficacy of a third-generation oncolytic herpes virus g47 delta in advanced stage models of human gastric cancer. Mol Ther-Oncolytics. 2020;17:205–15. doi:10.1016/j.omto.2020.03.022.
   PubMed Web of Science ®Google Scholar
• Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016;107(10):1373–79. doi:10.1111/cas.13027.
   PubMed Web of Science ®Google Scholar
• Taguchi S, Fukuhara H, Todo T. Oncolytic virus therapy in japan: progress in clinical trials and future perspectives. Jpn J Clin Oncol. 2019;49(3):201–09. doi:10.1093/jjco/hyy170.
   PubMed Web of Science ®Google Scholar
• Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, et al. Rindopepimut with temozolomide for patients with newly diagnosed, egfrviii-expressing glioblastoma (act iv): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017;18(10):1373–85. doi:10.1016/S1470-2045(17)30517-X.
   PubMed Web of Science ®Google Scholar
• Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D’-Andre SD, et al. First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018;16 (1) 142 .
   PubMedGoogle Scholar
• Narita Y, Arakawa Y, Yamasaki F, Nishikawa R, Aoki T, Kanamori M, Nagane M, Kumabe T, Hirose Y, Ichikawa T, et al. A randomized, double-blind, phase iii trial of personalized peptide vaccination for recurrent glioblastoma. Neuro Oncol. 2019;21(3):348–59. doi:10.1093/neuonc/noy200.
   PubMed Web of Science ®Google Scholar
• Weller M, Kaulich K, Hentschel B, Felsberg J, Gramatzki D, Pietsch T, Simon M, Westphal M, Schackert G, Tonn JC, et al. Assessment and prognostic significance of the epidermal growth factor receptor viii mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. Int J Cancer. 2014;134(10):2437–47. doi:10.1002/ijc.28576.
   PubMed Web of Science ®Google Scholar
• Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, Mrugala MM, Jensen R, Baehring JM, Sloan A, et al. A phase ii, multicenter trial of rindopepimut (cdx-110) in newly diagnosed glioblastoma: the act iii study. Neuro-Oncology. 2015;17(6):854–61. doi:10.1093/neuonc/nou348.
   PubMed Web of Science ®Google Scholar
• Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE II, McLendon RE, Mitchell DA, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant iii peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28(31):4722–29. doi:10.1200/JCO.2010.28.6963.
   PubMed Web of Science ®Google Scholar
• Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate egfrviii-expressing tumor cells in patients with glioblastoma. Neuro-Oncology. 2011;13(3):324–33. doi:10.1093/neuonc/noq157.
   PubMed Web of Science ®Google Scholar
• Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, et al. A vaccine targeting mutant idh1 induces antitumour immunity. Nature. 2014;512(7514):324±. doi:10.1038/nature13387.
   PubMed Web of Science ®Google Scholar
• Platten M, Schilling D, Bunse L, Wick A, Bunse T, Riehl D, Green E, Sanghvi K, Karapanagiotou-Schenkel I, Harting I, et al. Os6.4 noa-16: a first-in-man multicenter phase i clinical trial of the German neurooncology working group evaluating a mutation-specific peptide vaccine targeting idh1r132h in patients with newly diagnosed malignant astrocytomas. Neuro-Oncology. 2018;20:iii226–iii227. doi:10.1093/neuonc/noy139.041.
   Google Scholar
• Fenstermaker RA, Ciesielski MJ, Qiu J, Yang N, Frank CL, Lee KP, Mechtler LR, Belal A, Ahluwalia MS, Hutson AD. Clinical study of a survivin long peptide vaccine (survaxm) in patients with recurrent malignant glioma. Cancer Immunol Immunother. 2016;65(11):1339–52. doi:10.1007/s00262-016-1890-x.
   PubMed Web of Science ®Google Scholar
• Ahluwalia M, Reardon D, Abad A, Curry W, Wong E, Peereboom D, Belal A, Qiu J, Mogensen K, Schilero C, et al. Atim-41. Phase ii trial of a survivin vaccine (survaxm) for newly diagnosed glioblastoma. Neuro-Oncology. 2018;20(Suppl 6):vi10–vi11. doi:10.1093/neuonc/noy148.036.
   Google Scholar
• Andrews DW, Judy KD, Scott CB, Garcia S, Hooper DC. Phase ib clinical trial of igv-001 for patients with newly diagnosed glioblastoma. Clin Cancer Res. 2021;27(7):clincanres.3805.2020. doi:10.1158/1078-0432.CCR-20-3805.
   PubMed Web of Science ®Google Scholar
• Terasaki M, Soichiro S, Narita Y, Fujimaki T, Aoki T. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol. 2011;29(3):337–44. doi:10.1200/JCO.2010.29.7499.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69–74. doi:10.1126/science.aaa4971.
   PubMed Web of Science ®Google Scholar
• Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanovic S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019;565(7738):240±. doi:10.1038/s41586-018-0810-y.
   PubMed Web of Science ®Google Scholar
• Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E, et al. Neoantigen vaccine generates intratumoral t cell responses in phase ib glioblastoma trial. Nature. 2019;565(7738):234±. doi:10.1038/s41586-018-0792-9.
   PubMed Web of Science ®Google Scholar
• Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tonnesen P, Suso EMI, Saeboe-Larssen S, Sandberg C, Brinchmann JE, Helseth E, et al. Therapeutic vaccination against autologous cancer stem cells with mrna-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother. 2013;62(9):1499–509. doi:10.1007/s00262-013-1453-3.
   PubMed Web of Science ®Google Scholar
• Inoges S, Tejada S, de Cerio A-D, Perez-Larraya JG, Espinos J, Idoate MA, Dominguez PD, de Eulate RG, Aristu J, Bendandi M, et al. A phase ii trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. J Transl Med. 2017;15. doi:10.1186/s12967-017-1202-z
   PubMed Web of Science ®Google Scholar
• Buchroithner J, Erhart F, Pichler J, Widhalm G, Preusser M, Stockhammer G, Nowosielski M, Iglseder S, Freyschlag CE, Oberndorfer S, et al. Audencel immunotherapy based on dendritic cells has no effect on overall and progression-free survival in newly diagnosed glioblastoma: a phase ii randomized trial. Cancers. 2018;10(10):372. doi:10.3390/cancers10100372.
   PubMed Web of Science ®Google Scholar
• Patente TA, Pinho MP, Oliveira AA, Evangelista GCM, Bergami-Santos PC, Barbuto JAM. Human dendritic cells: their heterogeneity and clinical application potential in cancer immunotherapy. Front Immunol. 2019;9. doi:10.3389/fimmu.2018.03176.
   PubMed Web of Science ®Google Scholar
• Rutkowski S, De Vleeschouwer S, Kaempgen E, Wolff JEA, Kuhl J, Demaerel P, Warmuth-Metz M, Flamen P, Van Calenbergh F, Plets C, et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer. 2004;91(9):1656–62. doi:10.1038/sj.bjc.6602195.
   PubMed Web of Science ®Google Scholar
• Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial t-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005;11(15):5515–25. doi:10.1158/1078-0432.CCR-05-0464.
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, Yoshida S, Abe T, Narita M, Takahashi M, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase i/ii trial. Clin Cancer Res. 2005;11(11):4160–67. doi:10.1158/1078-0432.CCR-05-0120.
   PubMed Web of Science ®Google Scholar
• Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuno MA, Richardson JE, Fan X, Ji J, Chu RM, et al. Phase i trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother. 2013;62(1):125–35. doi:10.1007/s00262-012-1319-0.
   PubMed Web of Science ®Google Scholar
• Wen PY, Reardon DA, Armstrong TS, Phuphanich S, Aiken RD, Landolfi JC, Curry WT, Zhu J-J, Glantz M, Peereboom DM, et al. A randomized double-blind placebo-controlled phase ii trial of dendritic cell vaccine ict-107 in newly diagnosed patients with glioblastoma. Clin Cancer Res. 2019;25(19):5799–807. doi:10.1158/1078-0432.CCR-19-0261.
   PubMed Web of Science ®Google Scholar
• Shen S, Chen L, Liu J, Yang L, Zhang M, Wang L, Zhang R, Uemura Y, Wu Q, Yu X, et al. Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma. Cancer Biol & Med. 2020;17(3):555–68. doi:10.20892/j.issn.2095-3941.2020.0027.
   PubMed Web of Science ®Google Scholar
• Zhang N, Wei L, Ye M, Kang C, You H. Treatment progress of immune checkpoint blockade therapy for glioblastoma. Front Immunol. 2020;11:592612. doi:10.3389/fimmu.2020.592612.
   PubMed Web of Science ®Google Scholar
• Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–86. doi:10.1158/2159-8290.CD-18-0367.
   PubMed Web of Science ®Google Scholar
• Zappasodi R, Merghoub T, Wolchok JD. Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell. 2018;33(4):581–98. doi:10.1016/j.ccell.2018.03.005.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13. doi:10.1056/NEJMoa1510665.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39. doi:10.1056/NEJMoa1507643.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi:10.1056/NEJMoa1504030.
   PubMed Web of Science ®Google Scholar
• Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase i cohorts of checkmate 143. Neuro-Oncology. 2018;20(5):674–86. doi:10.1093/neuonc/nox208.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Baehr O, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma the checkmate 143 phase 3 randomized clinical trial. Jama Oncol. 2020;6(7):1003–10. doi:10.1001/jamaoncol.2020.1024.
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WKA, Paleologos N, Nicholas MK, Jensen R, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733–40. doi:10.1200/JCO.2008.19.8721.
   PubMed Web of Science ®Google Scholar
• Sahebjam S, Forsyth PA, Tran ND, Arrington JA, Macaulay R, Etame AB, Walko CM, Boyle T, Peguero EN, Jaglal M, et al. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase i study. Neuro-Oncology. 2021;23(4):677–86. doi:10.1093/neuonc/noaa260.
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, et al. Neoadjuvant anti-pd-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25(3):477±. doi:10.1038/s41591-018-0337-7.
   PubMed Web of Science ®Google Scholar
• Fife BT, Bluestone JA. Control of peripheral t-cell tolerance and autoimmunity via the ctla-4 and pd-1 pathways. Immunol Rev. 2008;224:166–82. doi:10.1111/j.1600-065X.2008.00662.x.
   PubMed Web of Science ®Google Scholar
• Harris-Bookman S, Mathios D, Martin AM, Xia Y, Kim E, Xu H, Belcaid Z, Polanczyk M, Barberi T, Theodros D, et al. Expression of lag-3 and efficacy of combination treatment with anti-lag-3 and anti-pd-1 monoclonal antibodies in glioblastoma. Int J Cancer. 2018;143(12):3201–08. doi:10.1002/ijc.31661.
   PubMed Web of Science ®Google Scholar
• Kim JE, Patel MA, Mangraviti A, Kim ES, Theodros D, Velarde E, Liu A, Sankey EW, Tam A, Xu H, et al. Combination therapy with anti-pd-1, anti-tim-3, and focal radiation results in regression of murine gliomas. Clin Cancer Res. 2017;23(1):124–36. doi:10.1158/1078-0432.CCR-15-1535.
   PubMed Web of Science ®Google Scholar
• Zhang M, Choi J, Lim M. Advances in immunotherapies for gliomas. Curr Neurol Neurosci Rep. 2022. doi:10.1007/s11910-022-01176-9.
   Web of Science ®Google Scholar
• Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, et al. Immune and genomic correlates of response to anti-pd-1 immunotherapy in glioblastoma. Nat Med. 2019;25(3):462±. doi:10.1038/s41591-019-0349-y.
   Web of Science ®Google Scholar
• Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S, Piantadosi S, Consortium NC. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011;17(16):5473–80. doi:10.1158/1078-0432.CCR-11-0774.
   PubMed Web of Science ®Google Scholar
• Pitter KL, Tamagno I, Alikhanyan K, Hosni-Ahmed A, Pattwell SS, Donnola S, Dai C, Ozawa T, Chang M, Chan TA, et al. Corticosteroids compromise survival in glioblastoma. Brain. 2016;139:1458–71. doi:10.1093/brain/aww046.
   PubMed Web of Science ®Google Scholar
• Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, Woroniecka K, Elsamadicy AA, Dechant CA, Kemeny HR, et al. Sequestration of t cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med. 2018;24(9):1459±. doi:10.1038/s41591-018-0135-2.
   PubMed Web of Science ®Google Scholar
• Yi JS, Cox MA, Zajac AJ. T-Cell exhaustion: characteristics, causes and conversion. Immunology. 2010;129(4):474–81. doi:10.1111/j.1365-2567.2010.03255.x.
   PubMed Web of Science ®Google Scholar
• Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. ‘Off-The-Shelf’ allogeneic car t cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185–99. doi:10.1038/s41573-019-0051-2.
   PubMed Web of Science ®Google Scholar